




Instance: composition-en-9cd7665100fd3b81b318cbcb65d45fef
InstanceOf: CompositionUvEpi
Title: "Composition for incresync Package Leaflet"
Description:  "Composition for incresync Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/13/842/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp9cd7665100fd3b81b318cbcb65d45fef)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - incresync"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  
  </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol type="1">
<li>What Incresync is and what it is used for</li>
<li>What you need to know before you take Incresync</li>
<li>How to take Incresync</li>
<li>Possible side effects</li>
<li>How to store Incresync</li>
<li>Contents of the pack and other information</li>
</ol>
 </div>"""   
          

* section[=].section[+]
  * title =  "1. What incresync is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What incresync is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2
id="what-incresync-is-incresync-contains-two-different-medicines-called-alogliptin-and-pioglitazone-in-one-tablet">What
Incresync is Incresync contains two different medicines called
alogliptin and pioglitazone in one tablet:</h2>
<h2
id="alogliptin-belongs-to-a-group-of-medicines-called-dpp-4-inhibitors-dipeptidyl-peptidase-4-inhibitors-alogliptin-works-to-increase-the-levels-of-insulin-in-the-body-after-a-meal-and-decrease-the-amount-of-sugar-in-the-body">alogliptin
belongs to a group of medicines called DPP-4 inhibitors (dipeptidyl
peptidase-4 inhibitors). Alogliptin works to increase the levels of
insulin in the body after a meal and decrease the amount of sugar in the
body.</h2>
<p>pioglitazone belongs to a group of medicines called
thiazolidinediones. It helps your body make better use of the insulin it
produces. Both of these groups of medicines are oral anti-diabetics .
What Incresync is used for Incresync is used to lower blood sugar levels
in adults with type 2 diabetes. Type 2 diabetes is also called
non-insulin-dependent diabetes mellitus or NIDDM. Incresync is taken
when your blood sugar cannot be adequately controlled by diet, exercise
and other oral anti-diabetic medicines such as pioglitazone; or
pioglitazone and metformin taken together. Your doctor will check
whether Incresync is working 3 to 6 months after you start taking it. If
you are already taking both alogliptin and pioglitazone as single
tablets, Incresync can replace them in one tablet. It is important that
you continue to follow the advice on diet and exercise that your nurse
or doctor has given you.</p>
 </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take incresync"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take incresync"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2 id="do-not-take-incresync">Do not take Incresync</h2>
<h2
id="if-you-are-allergic-to-alogliptin-pioglitazone-or-any-of-the-other-ingredients-of-this-medicine-listed-in-section-6">if
you are allergic to alogliptin, pioglitazone or any of the other
ingredients of this medicine (listed in section 6).</h2>
<h2
id="if-you-have-had-a-serious-allergic-reaction-to-any-other-similar-medicines-that-you-take-to-control-your-blood-sugar-symptoms-of-a-serious-allergic-reaction-may-include-rash-raised-red-patches-on-your-skin-hives-swelling-of-the-face-lips-tongue-and-throat-that-may-cause-difficulty-in-breathing-or-swallowing-additional-symptoms-may-include-general-itching-and-feeling-of-heat-especially-affecting-the-scalp-mouth-throat-palms-of-hands-and-soles-of-feet-stevens-johnson-syndrome">if
you have had a serious allergic reaction to any other similar medicines
that you take to control your blood sugar. Symptoms of a serious
allergic reaction may include; rash, raised red patches on your skin
(hives), swelling of the face, lips, tongue, and throat that may cause
difficulty in breathing or swallowing. Additional symptoms may include
general itching and feeling of heat especially affecting the scalp,
mouth, throat, palms of hands and soles of feet (Stevens-Johnson
syndrome).</h2>
<h2
id="if-you-have-heart-failure-or-have-had-heart-failure-in-the-past">if
you have heart failure or have had heart failure in the past.</h2>
<h2 id="if-you-have-liver-disease">if you have liver disease.</h2>
<h2
id="if-you-have-diabetic-ketoacidosis-a-serious-complication-of-poorly-controlled-diabetes-symptoms-include-excessive-thirst-frequent-urination-loss-of-appetite-nausea-or-vomiting-and-rapid-weight-loss">if
you have diabetic ketoacidosis (a serious complication of poorly
controlled diabetes). Symptoms include excessive thirst, frequent
urination, loss of appetite, nausea or vomiting and rapid weight
loss.</h2>
<h2 id="if-you-have-or-have-ever-had-bladder-cancer">if you have or have
ever had bladder cancer.</h2>
<h2
id="if-you-have-blood-in-your-urine-that-your-doctor-has-not-checked-do-not-take-incresync-and-get-your-doctor-to-check-your-urine-as-soon-as-possible-warnings-and-precautions-talk-to-your-doctor-or-pharmacist-before-taking-incresync">if
you have blood in your urine that your doctor has not checked. Do not
take Incresync and get your doctor to check your urine as soon as
possible. Warnings and precautions Talk to your doctor or pharmacist
before taking Incresync:</h2>
<h2
id="if-you-have-type-1-diabetes-your-body-does-not-produce-insulin">if
you have type 1 diabetes (your body does not produce insulin).</h2>
<h2
id="if-you-are-taking-an-anti-diabetic-medicine-known-as-sulphonylurea-eg-glipizide-tolbutamide-glibenclamide-or-insulin">if
you are taking an anti-diabetic medicine known as sulphonylurea (e.g.
glipizide, tolbutamide, glibenclamide) or insulin.</h2>
<h2
id="if-you-suffer-from-heart-disease-or-fluid-retention-if-you-take-anti-inflammatory-medicines-which-can-also-cause-fluid-retention-and-swelling-you-must-also-tell-your-doctor">if
you suffer from heart disease or fluid retention. If you take
anti-inflammatory medicines which can also cause fluid retention and
swelling, you must also tell your doctor.</h2>
<h2
id="if-you-are-elderly-and-are-taking-insulin-because-you-may-have-an-increased-risk-of-heart-problems">if
you are elderly and are taking insulin, because you may have an
increased risk of heart problems.</h2>
<h2
id="if-you-have-a-problem-with-your-liver-or-kidneys-before-you-start-taking-this-medicine-you-will-have-a-blood-sample-taken-to-check-your-liver-and-kidney-function-this-check-may-be-repeated-at-intervals-in-case-of-kidney-disease-your-doctor-may-reduce-the-dose-of-incresync">if
you have a problem with your liver or kidneys. Before you start taking
this medicine you will have a blood sample taken to check your liver and
kidney function. This check may be repeated at intervals. In case of
kidney disease, your doctor may reduce the dose of Incresync.</h2>
<h2
id="if-you-have-a-special-type-of-diabetic-eye-disease-called-macular-oedema-swelling-of-the-back-of-the-eye">if
you have a special type of diabetic eye disease called macular oedema
(swelling of the back of the eye).</h2>
<h2
id="if-you-have-cysts-on-your-ovaries-polycystic-ovarian-syndrome-there-may-be-an-increased-possibility-of-becoming-pregnant-because-you-may-ovulate-again-when-you-take-incresync-if-this-applies-to-you-use-appropriate-contraception-to-avoid-the-possibility-of-an-unplanned-pregnancy">if
you have cysts on your ovaries (polycystic ovarian syndrome). There may
be an increased possibility of becoming pregnant because you may ovulate
again when you take Incresync. If this applies to you, use appropriate
contraception to avoid the possibility of an unplanned pregnancy.</h2>
<h2
id="if-you-have-or-have-had-a-disease-of-the-pancreas-slight-changes-in-cell-counts-may-show-up-in-blood-tests-your-doctor-may-discuss-the-results-with-you-a-higher-number-of-bone-fractures-was-seen-in-patients-particularly-women-taking-pioglitazone-your-doctor-will-take-this-into-account-when-treating-your-diabetes-contact-your-doctor-if-you-encounter-blistering-of-the-skin-as-it-may-be-a-sign-for-a-condition-called-bullous-pemphigoid-your-doctor-may-ask-you-to-stop-alogliptin-children-and-adolescents-incresync-is-not-recommended-for-children-and-adolescents-under-18-years-due-to-the-lack-of-data-in-these-patients-other-medicines-and-incresync-tell-your-doctor-or-pharmacist-if-you-are-taking-have-recently-taken-or-might-take-any-other-medicines-in-particular-tell-your-doctor-or-pharmacist-if-you-are-taking-any-of-the-following">if
you have or have had a disease of the pancreas. Slight changes in cell
counts may show up in blood tests. Your doctor may discuss the results
with you. A higher number of bone fractures was seen in patients,
particularly women taking pioglitazone. Your doctor will take this into
account when treating your diabetes. Contact your doctor if you
encounter blistering of the skin, as it may be a sign for a condition
called bullous pemphigoid. Your doctor may ask you to stop alogliptin.
Children and adolescents Incresync is not recommended for children and
adolescents under 18 years due to the lack of data in these patients.
Other medicines and Incresync Tell your doctor or pharmacist if you are
taking, have recently taken or might take any other medicines. In
particular tell your doctor or pharmacist if you are taking any of the
following:</h2>
<h2 id="gemfibrozil-used-to-lower-cholesterol">gemfibrozil (used to
lower cholesterol)</h2>
<p>rifampicin (used to treat tuberculosis and other infections) Your
blood sugar will be checked and your dose of Incresync may need to be
changed. Pregnancy and breast-feeding If you are pregnant or
breast-feeding, think you may be pregnant or are planning to have a
baby, ask your doctor or pharmacist for advice before taking this
medicine. There is no experience of using Incresync in pregnant women or
during breast-feeding. Incresync should not be used during pregnancy or
breast-feeding. Driving and using machines You may experience visual
disturbances while taking this medicine. If this happens, do not drive
or use any tools or machines. Taking Incresync in combination with other
anti-diabetic medicines can cause low blood sugar levels
(hypoglycaemia), which may affect your ability to drive and use
machines. Incresync contains lactose If you have been told by your
doctor that you have intolerance to some sugars, contact your doctor
before taking Incresync. Incresync contains sodium This medicine
contains less than 1 mmol sodium (23 mg) per tablet, that is to say
essentially sodium-free .</p>
 </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take incresync"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take incresync"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has
told you. Check with your doctor or pharmacist if you are not sure. Your
doctor will tell you how much Incresync you need to take and if you need
to change the amount of other medicines you take. The maximum
recommended daily dose is one 25 mg/45 mg tablet. Incresync should be
taken once daily. Swallow your tablet(s) whole with water. You can take
this medicine with or without food. If you have kidney problems your
doctor may prescribe you a reduced dose. If you are following a diabetic
diet, you should continue with this while you are taking Incresync. Your
weight should be checked at regular intervals; if your weight increases,
tell your doctor. If you take more Incresync than you should If you take
more tablets than you should, or if someone else or a child takes your
medicine, contact or go to your nearest emergency centre straight away.
Take this leaflet or some tablets with you so that your doctor knows
exactly what you have taken. If you forget to take Incresync If you
forget to take a dose, take it as soon as you remember it. Do not take a
double dose to make up for a forgotten dose. If you stop taking
Incresync Do not stop taking Incresync without consulting your doctor
first. Your blood sugar levels may increase when you stop taking
Incresync. If you have any further questions on the use of this
medicine, ask your doctor or pharmacist.</p>
 </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2
id="like-all-medicines-this-medicine-can-cause-side-effects-although-not-everybody-gets-them-stop-taking-incresync-and-contact-a-doctor-immediately-if-you-notice-any-of-the-following-serious-side-effects-common-may-affect-up-to-1-in-10-people">Like
all medicines, this medicine can cause side effects, although not
everybody gets them. STOP taking Incresync and contact a doctor
immediately if you notice any of the following serious side effects:
Common (may affect up to 1 in 10 people):</h2>
<h2
id="sudden-and-severe-bone-pain-or-immobility-particularly-in-women-uncommon-may-affect-up-to-1-in-100-people">Sudden
and severe bone pain or immobility (particularly in women). Uncommon
(may affect up to 1 in 100 people):</h2>
<h2
id="symptoms-of-bladder-cancer-including-blood-in-your-urine-pain-when-urinating-or-a-sudden-need-to-urinate-not-known-frequency-cannot-be-estimated-from-the-available-data">Symptoms
of bladder cancer including blood in your urine, pain when urinating or
a sudden need to urinate. Not known (frequency cannot be estimated from
the available data):</h2>
<h2
id="an-allergic-reaction-the-symptoms-may-include-a-rash-hives-swallowing-or-breathing-problems-swelling-of-your-lips-face-throat-or-tongue-and-feeling-faint">An
allergic reaction. The symptoms may include: a rash, hives, swallowing
or breathing problems, swelling of your lips, face, throat or tongue and
feeling faint.</h2>
<h2
id="a-severe-allergic-reaction-skin-lesions-or-spots-on-your-skin-that-can-progress-to-a-sore-surrounded-by-pale-or-red-rings-blistering-andor-peeling-of-the-skin-possibly-with-symptoms-such-as-itching-fever-overall-ill-feeling-achy-joints-vision-problems-burning-painful-or-itchy-eyes-and-mouth-sores-stevens-johnson-syndrome-and-erythema-multiforme">A
severe allergic reaction: skin lesions or spots on your skin that can
progress to a sore surrounded by pale or red rings, blistering and/or
peeling of the skin possibly with symptoms such as itching, fever,
overall ill feeling, achy joints, vision problems, burning, painful or
itchy eyes and mouth sores (Stevens-Johnson syndrome and Erythema
multiforme).</h2>
<h2
id="severe-and-persistent-pain-in-the-abdomen-stomach-area-which-might-reach-through-to-your-back-as-well-as-nausea-and-vomiting-as-it-could-be-a-sign-of-an-inflamed-pancreas-pancreatitis-you-should-also-discuss-with-your-doctor-if-you-experience-the-following-side-effects-common">Severe
and persistent pain in the abdomen (stomach area) which might reach
through to your back, as well as nausea and vomiting, as it could be a
sign of an inflamed pancreas (pancreatitis). You should also discuss
with your doctor if you experience the following side effects:
Common:</h2>
<h2
id="symptoms-of-low-blood-sugar-hypoglycaemia-may-occur-when-incresync-is-taken-in-combination-with-insulin-or-sulphonylureas-eg-glipizide-tolbutamide-glibenclamide-symptoms-may-include-trembling-sweating-anxiety-blurred-vision-tingling-lips-paleness-mood-change-or-feeling-confused-your-blood-sugar-could-fall-below-the-normal-level-but-can-be-increased-again-by-taking-sugar-it-is-recommended-that-you-carry-some-sugar-lumps-sweets-biscuits-or-sugary-fruit-juice">Symptoms
of low blood sugar (hypoglycaemia) may occur when Incresync is taken in
combination with insulin or sulphonylureas (e.g. glipizide, tolbutamide,
glibenclamide). Symptoms may include: trembling, sweating, anxiety,
blurred vision, tingling lips, paleness, mood change or feeling
confused. Your blood sugar could fall below the normal level, but can be
increased again by taking sugar. It is recommended that you carry some
sugar lumps, sweets, biscuits or sugary fruit juice.</h2>
<h2
id="cold-or-flu-like-symptoms-such-as-sore-throat-stuffy-or-blocked-nose">Cold
or flu-like symptoms such as sore throat, stuffy or blocked nose</h2>
<h2 id="inflammation-of-the-sinuses-sinusitis">Inflammation of the
sinuses (sinusitis)</h2>
<h2 id="itchy-skin">Itchy skin</h2>
<h2 id="headache">Headache</h2>
<h2 id="stomach-ache">Stomach ache</h2>
<h2 id="diarrhoea">Diarrhoea</h2>
<h2 id="indigestion-heartburn">Indigestion, heartburn</h2>
<h2 id="feeling-sick">Feeling sick</h2>
<h2 id="muscle-pain">Muscle pain</h2>
<h2 id="feeling-numb-in-any-part-of-your-body">Feeling numb in any part
of your body</h2>
<h2 id="blurred-or-distorted-vision">Blurred or distorted vision</h2>
<h2 id="weight-gain">Weight gain</h2>
<h2 id="swollen-or-puffy-hands-or-feet">Swollen or puffy hands or
feet</h2>
<h2 id="rash-uncommon">Rash Uncommon:</h2>
<h2 id="difficulty-sleeping-not-known">Difficulty sleeping Not
known:</h2>
<h2
id="visual-disturbances-caused-by-a-condition-called-macular-oedema">Visual
disturbances (caused by a condition called macular oedema).</h2>
<h2
id="liver-problems-such-as-nausea-or-vomiting-stomach-pain-unusual-or-unexplained-tiredness-loss-of-appetite-dark-urine-or-yellowing-of-your-skin-or-the-whites-of-your-eyes">Liver
problems such as nausea or vomiting, stomach pain, unusual or
unexplained tiredness, loss of appetite, dark urine or yellowing of your
skin or the whites of your eyes.</h2>
<h2
id="inflammation-of-the-connective-tissue-within-the-kidneys-interstitial-nephritis">Inflammation
of the connective tissue within the kidneys (interstitial
nephritis).</h2>
<p>Blistering of the skin (bullous pemphigoid). Reporting of side
effects If you get any side effects, talk to your doctor or pharmacist.
This includes any possible side effects not listed in this leaflet. You
can also report side effects directly via the national reporting system
listed in Appendix V. By reporting side effects you can help provide
more information on the safety of this medicine.</p>
 </div>"""      
        
* section[=].section[+]
  * title = "5. How to store incresync"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store incresync"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. Do not use
this medicine after the expiry date which is stated on the carton and
blister after EXP. The expiry date refers to the last day of that month.
This medicinal product does not require any special temperature storage
conditions. Store in the original package in order to protect from
moisture. Do not throw away any medicines via wastewater or household
waste. Ask your pharmacist how to throw away medicines you no longer
use. These measures will help protect the environment.</p>
 </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2 id="what-incresync-contains">What Incresync contains</h2>
<h2
id="the-active-substances-are-alogliptin-and-pioglitazone-each-25-mg30-mg-film-coated-tablet-contains-alogliptin-benzoate-and-pioglitazone-hydrochloride-equivalent-to-25-mg-alogliptin-and-30-mg-pioglitazone">The
active substances are alogliptin and pioglitazone. Each 25 mg/30 mg
film-coated tablet contains alogliptin benzoate and pioglitazone
hydrochloride equivalent to 25 mg alogliptin and 30 mg
pioglitazone.</h2>
<h2
id="the-other-ingredients-are-mannitol-microcrystalline-cellulose-hydroxypropylcellulose-croscarmellose-sodium-magnesium-stearate-lactose-monohydrate-hypromellose-talc-titanium-dioxide-e171-yellow-iron-oxide-e172-red-iron-oxide-e172-macrogol-8000-shellac-and-black-iron-oxide-e172-see-section-2-incresync-contains-lactose--each-25-mg45-mg-film-coated-tablet-contains-alogliptin-benzoate-and-pioglitazone-hydrochloride-equivalent-to-25-mg-alogliptin-and-45-mg-pioglitazone">The
other ingredients are mannitol, microcrystalline cellulose,
hydroxypropylcellulose, croscarmellose sodium, magnesium stearate,
lactose monohydrate, hypromellose, talc, titanium dioxide (E171), yellow
iron oxide (E172), red iron oxide (E172), macrogol 8000, shellac and
black iron oxide (E172). See section 2 Incresync contains lactose . Each
25 mg/45 mg film-coated tablet contains alogliptin benzoate and
pioglitazone hydrochloride equivalent to 25 mg alogliptin and 45 mg
pioglitazone.</h2>
<h2
id="the-other-ingredients-are-mannitol-microcrystalline-cellulose-hydroxypropylcellulose-croscarmellose-sodium-magnesium-stearate-lactose-monohydrate-hypromellose-talc-titanium-dioxide-e171-red-iron-oxide-e172-macrogol-8000-shellac-and-black-iron-oxide-e172-see-section-2-incresync-contains-lactose--each125-mg30-mg-film-coated-tablet-contains-alogliptin-benzoate-and-pioglitazone-hydrochloride-equivalent-to-125-mg-alogliptin-and-30-mg-pioglitazone">The
other ingredients are mannitol, microcrystalline cellulose,
hydroxypropylcellulose, croscarmellose sodium, magnesium stearate,
lactose monohydrate, hypromellose, talc, titanium dioxide (E171), red
iron oxide (E172), macrogol 8000, shellac and black iron oxide (E172).
See section 2 Incresync contains lactose . Each12.5 mg/30 mg film-coated
tablet contains alogliptin benzoate and pioglitazone hydrochloride
equivalent to 12.5 mg alogliptin and 30 mg pioglitazone.</h2>
<h2
id="the-other-ingredients-are-mannitol-microcrystalline-cellulose-hydroxypropylcellulose-croscarmellose-sodium-magnesium-stearate-lactose-monohydrate-hypromellose-talc-titanium-dioxide-e171-yellow-iron-oxide-e172-red-iron-oxide-e172-macrogol-8000-shellac-carnauba-wax-and-glycerol-mono-oleate-see-section-2-incresync-contains-lactose--what-incresync-looks-like-and-contents-of-the-pack">The
other ingredients are mannitol, microcrystalline cellulose,
hydroxypropylcellulose, croscarmellose sodium, magnesium stearate,
lactose monohydrate, hypromellose, talc, titanium dioxide (E171), yellow
iron oxide (E172), red iron oxide (E172), macrogol 8000, shellac,
carnauba wax and glycerol mono-oleate. See section 2 Incresync contains
lactose . What Incresync looks like and contents of the pack</h2>
<h2
id="incresync-25-mg30-mg-film-coated-tablets-tablets-are-peach-round-approximately-87-mm-in-diameter-biconvex-film-coated-tablets-with-both-ap-and-2530-printed-in-grey-ink-on-one-side">Incresync
25 mg/30 mg film-coated tablets (tablets) are peach, round
(approximately 8.7 mm in diameter), biconvex, film-coated tablets, with
both A/P and 25/30 printed in grey ink on one side.</h2>
<h2
id="incresync-25-mg45-mg-film-coated-tablets-tablets-are-red-round-approximately-87-mm-in-diameter-biconvex-film-coated-tablets-with-both-ap-and-2545-printed-in-grey-ink-on-one-side">Incresync
25 mg/45 mg film-coated tablets (tablets) are red, round (approximately
8.7 mm in diameter), biconvex, film-coated tablets, with both A/P and
25/45 printed in grey ink on one side.</h2>
<p>Incresync 12.5 mg/30 mg film-coated tablets (tablets) are pale peach,
round (approximately 8.7 mm in diameter), biconvex, film-coated tablets,
with both A/P and 12.5/30 printed in red ink on one side. Incresync is
available in blister packs containing 10, 14, 28, 30, 56, 60, 90, 98 or
100 tablets. Not all pack sizes may be marketed. Marketing Authorisation
Holder Takeda Pharma A/S Delta Park 2665 Vallensbaek Strand Denmark
Manufacturer Takeda Ireland Limited Bray Business Park Kilruddery Co.
Wicklow Ireland For any information about this medicine, please contact
the local representative of the Marketing Authorisation Holder: Belgi
/Belgique/Belgien Takeda Belgium NV Tel/T l: +32 2 464 06 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> Lietuva
Takeda, UAB Tel: +370 521 09 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a></p>
<p>.: +359 2 958 27 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a>
Luxembourg/Luxemburg Takeda Belgium NV Tel/T l: +32 2 464 06 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> esk
republika Takeda Pharmaceuticals Czech Republic s.r.o. Tel: +420 234 722
<a href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a>
Magyarorsz g Takeda Pharma Kft. Tel: +36 1 270 <a
href="mailto:7medinfoEMEA@takeda.com">7medinfoEMEA@takeda.com</a>
Danmark Takeda Pharma A/S Tlf: +45 46 77 10 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> Malta
Takeda HELLAS S.A. Tel: +30 210 <a
href="mailto:6387medinfoEMEA@takeda.com">6387medinfoEMEA@takeda.com</a>
Deutschland Takeda GmbH Tel: +49 (0)800 825 <a
href="mailto:3medinfoEMEA@takeda.com">3medinfoEMEA@takeda.com</a>
Nederland Takeda Nederland B.V. Tel: +31 20 203 <a
href="mailto:5medinfoEMEA@takeda.com">5medinfoEMEA@takeda.com</a> Eesti
Takeda Pharma AS Tel: +372 6177 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> Norge
Takeda AS Tlf: +47 800 800 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a></p>
<p>Takeda . . : +30 210 <a
href="mailto:6387medinfoEMEA@takeda.com">6387medinfoEMEA@takeda.com</a>
sterreich Takeda Pharma Ges. m.b.H. Tel: +43 (0) 800-20 80 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> Espa a
Laboratorios Menarini, S.A Tel: +34 934 628 <a
href="mailto:info@menarini.es">info@menarini.es</a> Polska Takeda Pharma
Sp. z o.o. tel: <a
href="mailto:+48223062medinfoEMEA@takeda.com">+48223062medinfoEMEA@takeda.com</a>
France Takeda France SAS Tel: + 33 1 40 67 33 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> Portugal
Tecnimede - Sociedade T cnico-Medicinal, S.A Tel: +351 21 041 41 <a
href="mailto:dmed.fv@tecnimede.pt">dmed.fv@tecnimede.pt</a> Hrvatska
Takeda Pharmaceuticals Croatia d.o.o Tel: +385 1 377 88 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> Rom nia
Takeda Pharmaceuticals SRL Tel: +40 21 335 03 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> Ireland
Takeda Products Ireland Ltd Tel: 1800 937 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a>
Slovenija Takeda Pharmaceuticals farmacevtska dru ba d.o.o.. Tel: +386
(0) 59 082 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> sland
Vistor hf. S mi: +354 535 <a
href="mailto:7medinfoEMEA@takeda.com">7medinfoEMEA@takeda.com</a>
Slovensk republika Takeda Pharmaceuticals Slovakia s.r.o. Tel: +421 (2)
20 602 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> Italia
Takeda Italia S.p.A. Tel: +39 06 <a
href="mailto:502medinfoEMEA@takeda.com">502medinfoEMEA@takeda.com</a>
Suomi/Finland Takeda Oy Puh/Tel: 0800 774 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a></p>
<p>Takeda . . : +30 210 <a
href="mailto:6387medinfoEMEA@takeda.com">6387medinfoEMEA@takeda.com</a>
Sverige Takeda Pharma AB Tel: 020 795 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> Latvija
Takeda Latvia SIA Tel: +371 <a
href="mailto:67840medinfoEMEA@takeda.com">67840medinfoEMEA@takeda.com</a>
United Kingdom (Northern Ireland) Takeda UK Ltd Tel: +44 (0) 2830 640 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> This
leaflet was last revised in Other sources of information Detailed
information on this medicine is available on the European Medicines
Agency web site:</p>
 </div>"""      



Instance: composition-da-9cd7665100fd3b81b318cbcb65d45fef
InstanceOf: CompositionUvEpi
Title: "Composition for incresync Package Leaflet"
Description:  "Composition for incresync Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/13/842/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp9cd7665100fd3b81b318cbcb65d45fef)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - incresync"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. INDLÆGSSEDDEL"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. INDLÆGSSEDDEL"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Indlægsseddel: Information til brugeren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Indlægsseddel: Information til brugeren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  
  </div>"""   



* section[=].section[+]
  * title = "Oversigt over indlægssedlen"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Oversigt over indlægssedlen"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen</p>
<ol type="1">
<li>Virkning og anvendelse</li>
<li>Det skal du vide, før du begynder at tage Incresync</li>
<li>Sådan skal du tage Incresync</li>
<li>Bivirkninger</li>
<li>Opbevaring</li>
<li>Pakningsstørrelser og yderligere oplysninger.</li>
</ol>
 </div>"""   
          

* section[=].section[+]
  * title =  "1. Virkning og anvendelse"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. Virkning og anvendelse"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2
id="hvad-incresync-er-incresync-indeholder-to-forskellige-lægemidler-alogliptin-og-pioglitazon-i-én-tablet">Hvad
Incresync er Incresync indeholder to forskellige lægemidler, alogliptin
og pioglitazon, i én tablet:</h2>
<h2
id="alogliptin-tilhører-en-gruppe-af-lægemidler-der-kaldes-dpp-4-hæmmere-dipeptidyl-peptidase-4-hæmmere-alogliptin-virker-ved-at-øge-insulinniveauet-i-kroppen-efter-et-måltid-og-sænke-mængden-af-sukker-i-kroppen">alogliptin
tilhører en gruppe af lægemidler, der kaldes DPP-4-hæmmere (dipeptidyl
peptidase-4-hæmmere). Alogliptin virker ved at øge insulinniveauet i
kroppen efter et måltid og sænke mængden af sukker i kroppen.</h2>
<p>pioglitazon tilhører en gruppe af lægemidler, der kaldes
thiazolidindioner. Pioglitazon hjælper din krop med bedre at udnytte den
insulin, den producerer. Begge disse grupper af lægemidler er såkaldte
orale antidiabetika (diabetesmedicin til at indtage gennem munden). Hvad
Incresync bruges til Incresync sænker blodsukkeret hos voksne med type
2-diabetes. Type 2-diabetes kaldes også ikke-insulinkrævende diabetes
mellitus eller gammelmandssukkersyge. Du kan tage Incresync, hvis dit
blodsukker ikke kan styres godt nok gennem kost, motion og andre orale
antidiabetika såsom pioglitazon eller pioglitazon og metformin taget
samtidigt. Din læge tjekker, om Incresync virker tilfredsstillende, 3
til 6 måneder efter du er startet med at tage det. Hvis du allerede
tager både alogliptin og pioglitazon som separate tabletter, kan
Incresync erstatte dem begge. Det er vigtigt, at du bliver ved med at
følge de råd om kost og motion, som din læge eller sygeplejerske har
givet dig. 44</p>
 </div>"""   
          

             
* section[=].section[+]
  * title = "2. Det skal du vide, før du begynder at tage  incresync"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. Det skal du vide, før du begynder at tage  incresync"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2 id="tag-ikke-incresync">Tag ikke Incresync</h2>
<h2
id="hvis-du-er-allergisk-over-for-alogliptin-pioglitazon-eller-et-af-de-øvrige-indholdsstoffer-i-incresync-angivet-i-punkt-6">hvis
du er allergisk over for alogliptin, pioglitazon eller et af de øvrige
indholdsstoffer i Incresync (angivet i punkt 6).</h2>
<h2
id="hvis-du-har-haft-en-alvorlig-allergisk-reaktion-over-for-andre-lignende-lægemidler-som-du-tager-for-at-styre-dit-blodsukker-tegn-på-en-alvorlig-allergisk-reaktion-kan-være-udslæt-hævede-røde-områder-på-huden-nældefeber-og-hævelse-af-ansigt-læber-tunge-eller-svælg-som-kan-gøre-det-svært-for-dig-at-trække-vejret-eller-synke-de-tegn-du-skal-være-opmærksom-på-er-kløe-en-følelse-af-varme-især-i-hovedbund-mund-hals-håndflader-og-fodsåler-stevens-johnsons-syndrom">hvis
du har haft en alvorlig allergisk reaktion over for andre lignende
lægemidler, som du tager for at styre dit blodsukker. Tegn på en
alvorlig allergisk reaktion kan være udslæt, hævede røde områder på
huden (nældefeber) og hævelse af ansigt, læber, tunge eller svælg, som
kan gøre det svært for dig at trække vejret eller synke. De tegn, du
skal være opmærksom på, er kløe, en følelse af varme især i hovedbund,
mund, hals, håndflader og fodsåler (Stevens-Johnsons syndrom).</h2>
<h2
id="hvis-du-lider-af-hjertesvigt-eller-tidligere-har-haft-hjertesvigt">hvis
du lider af hjertesvigt eller tidligere har haft hjertesvigt.</h2>
<h2 id="hvis-du-har-en-leversygdom">hvis du har en leversygdom.</h2>
<h2
id="hvis-du-lider-af-diabetisk-ketoacidose-en-alvorlig-komplikation-ved-dårligt-reguleret-diabetes-de-symptomer-du-skal-være-opmærksom-på-er-udtalt-tørst-hyppig-vandladning-appetitløshed-kvalme-eller-opkastning-og-hurtigt-vægttab">hvis
du lider af diabetisk ketoacidose (en alvorlig komplikation ved dårligt
reguleret diabetes). De symptomer, du skal være opmærksom på, er udtalt
tørst, hyppig vandladning, appetitløshed, kvalme eller opkastning og
hurtigt vægttab.</h2>
<h2 id="hvis-du-lider-af-eller-tidligere-har-haft-blærecancer">hvis du
lider af eller tidligere har haft blærecancer.</h2>
<h2
id="hvis-du-har-blod-i-urinen-som-din-læge-ikke-har-undersøgt-undlad-at-tage-incresync-og-få-din-læge-til-at-tjekke-din-urin-hurtigst-muligt-advarsler-og-forsigtighedsregler-kontakt-lægen-eller-apotekspersonalet-før-du-tager-incresync">hvis
du har blod i urinen, som din læge ikke har undersøgt. Undlad at tage
Incresync, og få din læge til at tjekke din urin hurtigst muligt.
Advarsler og forsigtighedsregler Kontakt lægen eller apotekspersonalet,
før du tager Incresync:</h2>
<h2
id="hvis-du-har-type-1-diabetes-din-krop-kan-ikke-producere-insulin">hvis
du har type 1-diabetes (din krop kan ikke producere insulin).</h2>
<h2
id="hvis-du-tager-diabetesmedicin-af-typen-sulfonylurinstof-feks-glipizid-tolbutamid-glibenclamid-eller-insulin">hvis
du tager diabetesmedicin af typen sulfonylurinstof (f.eks. glipizid,
tolbutamid, glibenclamid) eller insulin.</h2>
<h2
id="hvis-du-lider-af-en-hjertesygdom-eller-af-væskeophobning-hvis-du-tager-antiinflammatorisk-medicin-som-også-kan-forårsage-væskeophobning-og-hævelse-skal-du-også-fortælle-din-læge-det">hvis
du lider af en hjertesygdom eller af væskeophobning. Hvis du tager
antiinflammatorisk medicin, som også kan forårsage væskeophobning og
hævelse, skal du også fortælle din læge det.</h2>
<h2
id="hvis-du-er-ældre-og-tager-insulin-fordi-du-kan-have-en-øget-risiko-for-hjerteproblemer">hvis
du er ældre og tager insulin, fordi du kan have en øget risiko for
hjerteproblemer.</h2>
<h2
id="hvis-du-har-problemer-med-lever-eller-nyrer-før-du-begynder-at-tage-incresync-vil-du-få-taget-en-blodprøve-til-kontrol-af-lever--og-nyrefunktion-denne-kontrol-skal-måske-udføres-løbende-hvis-du-har-en-nyresygdom-vil-din-læge-muligvis-nedsætte-dosen-af-incresync">hvis
du har problemer med lever eller nyrer. Før du begynder at tage
Incresync, vil du få taget en blodprøve til kontrol af lever- og
nyrefunktion. Denne kontrol skal måske udføres løbende. Hvis du har en
nyresygdom, vil din læge muligvis nedsætte dosen af Incresync.</h2>
<h2
id="hvis-du-lider-af-en-særlig-diabetisk-øjenlidelse-som-hedder-makulaødem-væskeansamling-i-det-bagerste-af-øjet">hvis
du lider af en særlig diabetisk øjenlidelse, som hedder makulaødem
(væskeansamling i det bagerste af øjet).</h2>
<h2
id="hvis-du-har-cyster-på-æggestokkene-polycystisk-ovariesyndrom-der-kan-være-større-sandsynlighed-for-at-blive-gravid-fordi-du-kan-få-ægløsning-igen-når-du-tager-incresync-hvis-dette-er-relevant-for-dig-skal-du-anvende-sikker-prævention-så-du-undgår-uønsket-graviditet">hvis
du har cyster på æggestokkene (polycystisk ovariesyndrom). Der kan være
større sandsynlighed for at blive gravid, fordi du kan få ægløsning
igen, når du tager Incresync. Hvis dette er relevant for dig, skal du
anvende sikker prævention, så du undgår uønsket graviditet.</h2>
<h2
id="hvis-du-har-eller-har-haft-sygdom-i-bugspytkirtlen-blodprøverne-kan-vise-små-ændringer-i-dine-blodværdier-din-læge-vil-muligvis-tale-med-dig-om-det-der-er-set-et-øget-antal-knoglebrud-hos-patienter-især-kvinder-der-tager-pioglitazon-din-læge-vil-tage-dette-i-betragtning-ved-planlægning-af-din-behandling-kontakt-lægen-hvis-du-får-blærer-på-huden-da-det-kan-være-tegn-på-en-sygdom-der-hedder-bulløs-pemfigoid-din-læge-vil-muligvis-bede-dig-om-at-holde-op-med-at-tage-alogliptin-børn-og-unge-incresync-anbefales-ikke-til-børn-og-unge-under-18-år-da-der-ikke-foreligger-tilstrækkelige-data-for-denne-aldersgruppe-brug-af-anden-medicin-sammen-med-incresync-fortæl-det-altid-til-lægen-eller-apotekspersonalet-hvis-du-tager-anden-medicin-for-nylig-har-taget-anden-medicin-eller-planlægger-at-tage-anden-medicin-dette-gælder-også-medicin-som-ikke-er-købt-på-recept-feks-naturlægemidler-og-vitaminer-og-mineraler-45-det-er-især-vigtigt-at-du-fortæller-det-til-lægen-hvis-du-i-forvejen-tager-et-af-disse-lægemidler">hvis
du har eller har haft sygdom i bugspytkirtlen. Blodprøverne kan vise små
ændringer i dine blodværdier. Din læge vil muligvis tale med dig om det.
Der er set et øget antal knoglebrud hos patienter, især kvinder, der
tager pioglitazon. Din læge vil tage dette i betragtning ved planlægning
af din behandling. Kontakt lægen, hvis du får blærer på huden, da det
kan være tegn på en sygdom, der hedder bulløs pemfigoid. Din læge vil
muligvis bede dig om at holde op med at tage alogliptin. Børn og unge
Incresync anbefales ikke til børn og unge under 18 år, da der ikke
foreligger tilstrækkelige data for denne aldersgruppe. Brug af anden
medicin sammen med Incresync Fortæl det altid til lægen eller
apotekspersonalet, hvis du tager anden medicin for, nylig har taget
anden medicin eller planlægger at tage anden medicin. Dette gælder også
medicin, som ikke er købt på recept, f.eks. naturlægemidler og vitaminer
og mineraler. 45 Det er især vigtigt, at du fortæller det til lægen,
hvis du i forvejen tager et af disse lægemidler:</h2>
<h2 id="gemfibrozil-bruges-til-at-sænke-kolesterol">gemfibrozil (bruges
til at sænke kolesterol)</h2>
<p>rifampicin (bruges til at behandle tuberkulose og andre
infektionssygdomme). Du vil få kontrolleret blodsukkeret for at se, om
du skal have ændret doseringen af Incresync. Graviditet og amning Hvis
du er gravid eller ammer, har mistanke om, at du er gravid, eller
planlægger at blive gravid, skal du spørge din læge eller
apotekspersonalet til råds, før du tager dette lægemiddel. Der er ingen
erfaringer med brug af Incresync til gravide eller ammende kvinder. Du
må ikke tage Incresync, hvis du er gravid eller ammer. Trafik- og
arbejdssikkerhed Du kan opleve synsforstyrrelser, når du tager
Incresync. Hvis dette sker, må du ikke køre bil eller betjene værktøj
eller maskiner. Hvis du tager Incresync samtidig med anden
diabetesmedicin, kan du få for lavt blodsukker (hypoglykæmi), hvilket
kan påvirke din evne til at køre bil og betjene maskiner. Incresync
indeholder lactose Kontakt lægen, før du tager denne medicin, hvis lægen
har fortalt dig, at du ikke kan tåle visse sukkerarter. Incresync
indeholder natrium Dette lægemiddel indeholder mindre end 1 mmol (23 mg)
natrium pr. tablet, dvs. det er i det væsentlige natriumfrit.</p>
 </div>"""   
                    
* section[=].section[+]
  * title =  "3. Sådan skal du tage incresync"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. Sådan skal du tage incresync"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens, eller apotekspersonalets
anvisning. Er du i tvivl, så spørg lægen, eller apotekspersonalet. Lægen
fortæller dig, hvor meget Incresync du skal tage, og om du skal ændre
mængden af andre lægemidler, du tager. Den højeste anbefalede dosis er
én 25 mg/45 mg-tablet dagligt. Incresync skal tages én gang dagligt.
Synk tabletten hel sammen med vand. Du kan tage Incresync med eller uden
et måltid. Hvis du har nyreproblemer, vil din læge muligvis ordinere en
lavere dosis til dig. Hvis du følger en diabetesdiæt, skal du fortsætte
med denne, mens du tager Incresync. Din vægt bør tjekkes med jævne
mellemrum, og hvis den stiger, skal du kontakte din læge. Hvis du har
taget for meget Incresync Hvis du har taget flere tabletter, end du
skulle, eller hvis en anden person, f.eks. et barn, tager dine
tabletter, skal du kontakte læge eller søge til den nærmeste skadestue
med det samme. Tag denne indlægsseddel eller nogle tabletter med, så
lægen nøjagtigt ved, hvad der er indtaget. Hvis du har glemt at tage
Incresync Hvis du har glemt at tage en dosis, skal du tage den så snart,
du kommer i tanke om det. Du må ikke tage en dobbeltdosis som erstatning
for den glemte dosis. 46 Hvis du holder op med at tage Incresync Hold
ikke op med at tage Incresync uden at tale med din læge først. Dit
blodsukker kan blive højere, når du holder op med at tage Incresync.
Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl
om.</p>
 </div>"""         

        
* section[=].section[+]
  * title = "4. Bivirkninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Bivirkninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2
id="dette-lægemiddel-kan-som-alle-andre-lægemidler-give-bivirkninger-men-ikke-alle-får-bivirkninger-stop-med-at-tage-incresync-og-kontakt-lægen-med-det-samme-hvis-du-får-en-eller-flere-af-de-følgende-alvorlige-bivirkninger-almindelige-bivirkninger-forekommer-hos-op-til-1-ud-af-10-personer">Dette
lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke
alle får bivirkninger. STOP med at tage Incresync, og kontakt lægen med
det samme, hvis du får en eller flere af de følgende alvorlige
bivirkninger: Almindelige bivirkninger (forekommer hos op til 1 ud af 10
personer):</h2>
<h2
id="pludselige-og-stærke-knoglesmerter-eller-ubevægelighed-særligt-hos-kvinder-ikke-almindelige-bivirkninger-forekommer-hos-op-til-1-ud-af-100-personer">Pludselige
og stærke knoglesmerter eller ubevægelighed (særligt hos kvinder). Ikke
almindelige bivirkninger (forekommer hos op til 1 ud af 100
personer):</h2>
<h2
id="symptomer-på-blærecancer-herunder-blod-i-urinen-smerter-ved-vandladning-og-pludselig-vandladningstrang-bivirkninger-med-ukendt-hyppighed-hyppigheden-kan-ikke-bestemmes-ud-fra-de-foreliggende-data">Symptomer
på blærecancer, herunder blod i urinen, smerter ved vandladning og
pludselig vandladningstrang. Bivirkninger med ukendt hyppighed
(hyppigheden kan ikke bestemmes ud fra de foreliggende data):</h2>
<h2
id="en-allergisk-reaktion-tegnene-kan-være-udslæt-nældefeber-synke--eller-åndedrætsbesvær-opsvulmede-læber-ansigt-svælg-eller-tunge-og-besvimelsesfornemmelse">En
allergisk reaktion. Tegnene kan være udslæt, nældefeber, synke- eller
åndedrætsbesvær, opsvulmede læber, ansigt, svælg eller tunge og
besvimelsesfornemmelse.</h2>
<h2
id="en-alvorlig-allergisk-reaktion-hudlæsioner-eller-pletter-på-huden-der-kan-udvikle-sig-til-et-sår-omgivet-af-blege-eller-røde-ringe-blæredannelse-ogeller-afskalning-af-huden-eventuelt-med-symptomer-som-kløe-feber-generel-utilpashed-smertende-led-synsforstyrrelser-brændende-smertefuld-eller-kløende-øjne-og-sår-i-munden-steven-johnson-syndrome-og-erythema-multiforme">En
alvorlig allergisk reaktion: hudlæsioner eller pletter på huden, der kan
udvikle sig til et sår omgivet af blege eller røde ringe, blæredannelse
og/eller afskalning af huden eventuelt med symptomer som kløe, feber,
generel utilpashed, smertende led, synsforstyrrelser, brændende
smertefuld eller kløende øjne og sår i munden (Steven-Johnson syndrome
og erythema multiforme).</h2>
<h2
id="stærke-og-vedvarende-smerter-i-maven-som-kan-stråle-ud-i-ryggen-samt-kvalme-og-opkastning-det-kan-være-tegn-på-betændelse-i-bugspytkirtlen-pancreatitis-du-skal-også-fortælle-din-læge-hvis-du-får-følgende-bivirkninger-almindelige-bivirkninger">Stærke
og vedvarende smerter i maven, som kan stråle ud i ryggen, samt kvalme
og opkastning. Det kan være tegn på betændelse i bugspytkirtlen
(pancreatitis). Du skal også fortælle din læge, hvis du får følgende
bivirkninger: Almindelige bivirkninger:</h2>
<h2
id="tegn-på-lavt-blodsukker-hypoglykæmi-som-kan-opstå-hvis-incresync-tages-i-kombination-med-insulin-eller-sulfonylurinstof-feks-glipizid-tolbutamid-eller-glibenclamid-tegnene-kan-være-rysten-svedtendens-angst-sløret-syn-prikkende-fornemmelse-i-læber-bleghed-humørsvingninger-eller-forvirring-blodsukkeret-kan-falde-til-under-det-normale-niveau-men-kan-bringes-til-at-stige-igen-hvis-du-indtager-sukker-det-anbefales-at-du-altid-medbringer-lidt-sukkerknalder-slik-kiks-eller-sukkerholdig-frugtjuice">Tegn
på lavt blodsukker (hypoglykæmi), som kan opstå, hvis Incresync tages i
kombination med insulin eller sulfonylurinstof (f.eks. glipizid,
tolbutamid eller glibenclamid). Tegnene kan være rysten, svedtendens,
angst, sløret syn, prikkende fornemmelse i læber, bleghed,
humørsvingninger eller forvirring. Blodsukkeret kan falde til under det
normale niveau, men kan bringes til at stige igen, hvis du indtager
sukker. Det anbefales, at du altid medbringer lidt sukkerknalder, slik,
kiks eller sukkerholdig frugtjuice.</h2>
<h2
id="forkølelse-eller-influenzalignende-symptomer-som-ondt-i-halsen-og-tilstoppet-næse">forkølelse
eller influenzalignende symptomer som ondt i halsen og tilstoppet
næse</h2>
<h2 id="bihulebetændelse-sinusitis">bihulebetændelse (sinusitis)</h2>
<h2 id="hudkløe">hudkløe</h2>
<h2 id="hovedpine">hovedpine</h2>
<h2 id="mavesmerter">mavesmerter</h2>
<h2 id="diarré">diarré</h2>
<h2 id="fordøjelsesbesvær-opstød">fordøjelsesbesvær, opstød</h2>
<h2 id="almen-sygdomsfornemmelse">almen sygdomsfornemmelse</h2>
<h2 id="muskelsmerter">muskelsmerter</h2>
<h2 id="følelsesløshed-i-en-del-af-kroppen">følelsesløshed i en del af
kroppen</h2>
<h2 id="sløret-eller-forvrænget-syn">sløret eller forvrænget syn</h2>
<h2 id="vægtforøgelse">vægtforøgelse</h2>
<h2 id="hævede-hænder-eller-fødder">hævede hænder eller fødder</h2>
<h2 id="udslæt-47-ikke-almindelige-bivirkninger">udslæt 47 Ikke
almindelige bivirkninger:</h2>
<h2 id="søvnbesvær-bivirkninger-med-ukendt-hyppighed">søvnbesvær
Bivirkninger med ukendt hyppighed:</h2>
<h2
id="synsforstyrrelser-forårsaget-af-en-diabetisk-øjenlidelse-kaldet-makulaødem">synsforstyrrelser
(forårsaget af en diabetisk øjenlidelse kaldet makulaødem)</h2>
<h2
id="leverproblemer-der-viser-sig-som-kvalme-opkastning-mavesmerter-usædvanlig-eller-uforklarlig-træthed-manglende-appetit-mørkfarvet-urin-eller-gulfarvning-af-huden-eller-det-hvide-i-øjnene">leverproblemer,
der viser sig som kvalme, opkastning, mavesmerter, usædvanlig eller
uforklarlig træthed, manglende appetit, mørkfarvet urin eller
gulfarvning af huden eller det hvide i øjnene</h2>
<h2
id="betændelse-i-bindevævet-i-nyrerne-interstitiel-nefritis">betændelse
i bindevævet i nyrerne (interstitiel nefritis)</h2>
<p>blærer på huden (bulløs pemfigoid). Indberetning af bivirkninger Hvis
du oplever bivirkninger, bør du tale med din læge eller
apotekspersonalet. Dette gælder også mulige bivirkninger, som ikke er
medtaget i denne indlægsseddel. Du eller dine pårørende kan også
indberette bivirkninger direkte til Lægemiddelstyrelsen via det
nationale rapporteringssystem anført i Appendiks V. Ved at indrapportere
bivirkninger kan du hjælpe med at fremskaffe mere information om
sikkerheden af dette lægemiddel.</p>
 </div>"""      
        
* section[=].section[+]
  * title = "5. Opbevaring"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. Opbevaring"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. Brug ikke Incresync efter
den udløbsdato, der står på æsken og blisterkortet efter EXP.
Udløbsdatoen er den sidste dag i den nævnte måned. Der er ingen særlige
krav vedrørende opbevaringstemperaturer for dette lægemiddel. Opbevares
i den originale yderpakning for at beskytte mod fugt. Spørg
apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn
til miljøet må du ikke smide medicinrester i afløbet, toilettet eller
skraldespanden.</p>
 </div>"""      
        
        
* section[=].section[+]
  * title = "6. Pakningsstørrelser og yderligere oplysninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Pakningsstørrelser og yderligere oplysninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2 id="incresync-indeholder">Incresync indeholder:</h2>
<h2
id="aktive-stoffer-alogliptin-og-pioglitazon-hver-25-mg30-mg-filmovertrukken-tablet-indeholder-alogliptinbenzoat-og-pioglitazonhydrochlorid-svarende-til-25-mg-alogliptin-og-30-mg-pioglitazon">Aktive
stoffer: alogliptin og pioglitazon. Hver 25 mg/30 mg filmovertrukken
tablet indeholder alogliptinbenzoat og pioglitazonhydrochlorid svarende
til 25 mg alogliptin og 30 mg pioglitazon.</h2>
<h2
id="øvrige-indholdsstoffer-mannitol-mikrokrystallinsk-cellulose-hydroxypropylcellulose-croscarmelosenatrium-magnesiumstearat-lactosemonohydrat-hypromellose-talkum-titandioxid-e171-gul-jernoxid-e172-rød-jernoxid-e172-macrogol-8000-shellac-og-sort-jernoxid-e172-se-punkt-2-incresync-indeholder-lactose-hver-25-mg45-mg-filmovertrukken-tablet-indeholder-alogliptinbenzoat-og-pioglitazonhydrochlorid-svarende-til-25-mg-alogliptin-og-45-mg-pioglitazon">Øvrige
indholdsstoffer: mannitol, mikrokrystallinsk cellulose,
hydroxypropylcellulose, croscarmelosenatrium, magnesiumstearat,
lactosemonohydrat, hypromellose, talkum, titandioxid (E171), gul
jernoxid (E172), rød jernoxid (E172), macrogol 8000, shellac, og sort
jernoxid (E172). Se punkt 2 "Incresync indeholder lactose". Hver 25
mg/45 mg filmovertrukken tablet indeholder alogliptinbenzoat og
pioglitazonhydrochlorid svarende til 25 mg alogliptin og 45 mg
pioglitazon.</h2>
<h2
id="øvrige-indholdsstoffer-mannitol-mikrokrystallinsk-cellulose-hydroxypropylcellulose-croscarmelosenatrium-magnesiumstearat-lactosemonohydrat-hypromellose-talkum-titandioxid-e171-rød-jernoxid-e172-macrogol-8000-shellac-og-sort-jernoxid-e172-se-punkt-2-incresync-indeholder-lactose-hver-125-mg30-mg-filmovertrukken-tablet-indeholder-alogliptinbenzoat-og-pioglitazonhydrochlorid-svarende-til-125-mg-alogliptin-og-30-mg-pioglitazon">Øvrige
indholdsstoffer: mannitol, mikrokrystallinsk cellulose,
hydroxypropylcellulose, croscarmelosenatrium, magnesiumstearat,
lactosemonohydrat, hypromellose, talkum, titandioxid (E171), rød
jernoxid (E172), macrogol 8000, shellac, og sort jernoxid (E172). Se
punkt 2 "Incresync indeholder lactose". Hver 12,5 mg/30 mg
filmovertrukken tablet indeholder alogliptinbenzoat og
pioglitazonhydrochlorid svarende til 12,5 mg alogliptin og 30 mg
pioglitazon.</h2>
<h2
id="øvrige-indholdsstoffer-mannitol-mikrokrystallinsk-cellulose-hydroxypropylcellulose-croscarmelosenatrium-magnesiumstearat-lactosemonohydrat-hypromellose-talkum-titandioxid-e171-gul-jernoxid-e172-rød-jernoxid-e172-macrogol-8000-shellac-carnaubavoks-og-glycerol-mono-oleat-se-punkt-2-incresync-indeholder-lactose-48-udseende-og-pakningstørrelser">Øvrige
indholdsstoffer: mannitol, mikrokrystallinsk cellulose,
hydroxypropylcellulose, croscarmelosenatrium, magnesiumstearat,
lactosemonohydrat, hypromellose, talkum, titandioxid (E171), gul
jernoxid (E172), rød jernoxid (E172), macrogol 8000, shellac,
carnaubavoks og glycerol mono-oleat. Se punkt 2 "Incresync indeholder
lactose". 48 Udseende og pakningstørrelser</h2>
<h2
id="incresync-25-mg30-mg-filmovertrukne-tabletter-tabletter-er-ferskenfarvede-runde-ca-87-mm-i-diameter-bikonvekse-filmovertrukne-tabletter-med-både-ap-og2530-trykt-i-gråt-på-den-ene-side">Incresync
25 mg/30 mg filmovertrukne tabletter (tabletter) er ferskenfarvede,
runde (ca. 8,7 mm i diameter), bikonvekse, filmovertrukne tabletter med
både "A/P" og"25/30" trykt i gråt på den ene side.</h2>
<h2
id="incresync-25-mg45-mg-filmovertrukne-tabletter-tabletter-er-røde-runde-ca-87-mm-i-diameter-bikonvekse-filmovertrukne-tabletter-med-både-ap-og2545-trykt-i-gråt-på-den-ene-side">Incresync
25 mg/45 mg filmovertrukne tabletter (tabletter) er røde, runde (ca. 8,7
mm i diameter), bikonvekse, filmovertrukne tabletter med både "A/P"
og"25/45" trykt i gråt på den ene side.</h2>
<p>Incresync 12,5 mg/30 mg filmovertrukne tabletter (tabletter) er svagt
ferskenfarvede, runde (ca. 8,7 mm i diameter), bikonvekse,
filmovertrukne tabletter med både "A/P" og"12.5/30" trykt i rødt på den
ene side. Incresync fås i blisterpakninger indeholdende 10, 14, 28, 30,
56, 60, 90, 98 eller 100 tabletter. Ikke alle pakningsstørrelser er
nødvendigvis markedsført. Indehaver af markedsføringstilladelsen Takeda
Pharma A/S Delta Park 45 2665 Vallensbæk Strand Danmark Fremstiller
Takeda Ireland Limited Bray Business Park Kilruddery Co. Wicklow Irland
Hvis du ønsker yderligere oplysninger om Incresync, skal du henvende dig
til den lokale repræsentant for indehaveren af
markedsføringstilladelsen: België/Belgique/Belgien Takeda Belgium NV
Tel/Tél: +32 2 464 06 11 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> Lietuva
Takeda, UAB Tel: +370 521 09 070 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> България
Такеда България ЕООД Тел.: +359 2 958 27 36 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a>
Luxembourg/Luxemburg Takeda Belgium NV Tel/Tél: +32 2 464 06 11 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> Česká
republika Takeda Pharmaceuticals Czech Republic s.r.o. Tel: +420 234 722
722 <a href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a>
Magyarország Takeda Pharma Kft. Tel: +36 1 270 7030 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> Danmark
Takeda Pharma A/S Tlf: +45 46 77 10 10 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> Malta
Takeda HELLAS S.A. Tel: +30 210 6387800 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> 49
Deutschland Takeda GmbH Tel: +49 (0)800 825 3325 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a>
Nederland Takeda Nederland B.V. Tel: +31 20 203 5492 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> Eesti
Takeda Pharma AS Tel: +372 6177 669 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> Norge
Takeda AS Tlf: +47 800 800 30 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> Ελλάδα
Takeda ΕΛΛΑΣ Α.Ε. Τηλ: +30 210 6387800 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a>
Österreich Takeda Pharma Ges. m.b.H. Tel: +43 (0) 800-20 80 50 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> España
Laboratorios Menarini, S.A Tel: +34 934 628 800 <a
href="mailto:info@menarini.es">info@menarini.es</a> Polska Takeda Pharma
Sp. z o.o. tel: +48223062447 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> France
Takeda France SAS Tel: + 33 1 40 67 33 00 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> Portugal
Tecnimede - Sociedade Técnico-Medicinal, S.A Tel: +351 21 041 41 <a
href="mailto:dmed.fv@tecnimede.pt">dmed.fv@tecnimede.pt</a> Hrvatska
Takeda Pharmaceuticals Croatia d.o.o Tel: +385 1 377 88 96 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> România
Takeda Pharmaceuticals SRL Tel: +40 21 335 03 91 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> Ireland
Takeda Products Ireland Ltd Tel: 1800 937 970 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a>
Slovenija Takeda Pharmaceuticals farmacevtska družba d.o.o.. Tel: +386
(0) 59 082 480 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> Ísland
Vistor hf. Sími: +354 535 7000 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a>
Slovenská republika Takeda Pharmaceuticals Slovakia s.r.o. Tel: +421 (2)
20 602 600 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> Italia
Takeda Italia S.p.A. Tel: +39 06 502601 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a>
Suomi/Finland Takeda Oy Puh/Tel: 0800 774 051 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> Κύπρος
Takeda ΕΛΛΑΣ Α.Ε. Τηλ: +30 210 6387800 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> Sverige
Takeda Pharma AB Tel: 020 795 079 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> Latvija
Takeda Latvia SIA Tel: +371 67840082 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> United
Kingdom (Northern Ireland) Takeda UK Ltd Tel: +44 (0) 2830 640 902 <a
href="mailto:medinfoEMEA@takeda.com">medinfoEMEA@takeda.com</a> 50 Denne
indlægsseddel blev senest ændret Andre informationskilder Du kan finde
yderligere oplysninger om dette lægemiddel på Det Europæiske
Lægemiddelagenturs hjemmeside <a
href="http://www.ema.europa.eu">http://www.ema.europa.eu</a>.</p>
 </div>"""      





                    
Instance: bundlepackageleaflet-en-9cd7665100fd3b81b318cbcb65d45fef
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for incresync Package Leaflet for language en"
Description: "ePI document Bundle for incresync Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-9cd7665100fd3b81b318cbcb65d45fef"
* entry[0].resource = composition-en-9cd7665100fd3b81b318cbcb65d45fef

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp9cd7665100fd3b81b318cbcb65d45fef"
* entry[=].resource = mp9cd7665100fd3b81b318cbcb65d45fef
                            
                    
Instance: bundlepackageleaflet-da-9cd7665100fd3b81b318cbcb65d45fef
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for incresync Package Leaflet for language da"
Description: "ePI document Bundle for incresync Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-9cd7665100fd3b81b318cbcb65d45fef"
* entry[0].resource = composition-da-9cd7665100fd3b81b318cbcb65d45fef

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp9cd7665100fd3b81b318cbcb65d45fef"
* entry[=].resource = mp9cd7665100fd3b81b318cbcb65d45fef
                            
                    



Instance: mp9cd7665100fd3b81b318cbcb65d45fef
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Incresync 12.5 mg/30 mg film-coated tablets"
Description: "Incresync 12.5 mg/30 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/13/842/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Incresync 12.5 mg/30 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 9cd7665100fd3b81b318cbcb65d45fefListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "incresync"

* status = #current
* mode = #working

* title = "List of all ePIs associated with incresync"

* subject = Reference(mp9cd7665100fd3b81b318cbcb65d45fef)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#incresync "incresync"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-9cd7665100fd3b81b318cbcb65d45fef) // incresync en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-9cd7665100fd3b81b318cbcb65d45fef) // incresync da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-9cd7665100fd3b81b318cbcb65d45fef
InstanceOf: List
Description: "ePI document List for incresync Package Leaflets"

* insert 9cd7665100fd3b81b318cbcb65d45fefListRuleset
    